Former Goldman Sachs Executive Joins Nuvelo Board of Directors
Wednesday February 4, 5:05 pm ET
SUNNYVALE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO - News) today announced the appointment of Barry L. Zubrow, a former senior executive of The Goldman Sachs Group, Inc., to its board of directors. Mr. Zubrow will replace Thomas McCarter who stepped down as a member of the board of directors effective February 3, 2004. Mr. Zubrow will also replace Mr. McCarter on the audit committee.
"Thomas has served as a member of our board for several years, on two separate occasions, and I want to personally thank him for his contributions," said Dr. George Rathmann, chairman of Nuvelo's board of directors. "We wish him well in his future endeavors."
Mr. Zubrow brings over 26 years of corporate finance experience to Nuvelo's board of directors. From 1977 to 2003, Mr. Zubrow held a variety of positions at The Goldman Sachs Group (Goldman, Sachs & Co.) including chief administrative officer and head of the operations and the administration division. As the firm's first chief administrative officer, he was responsible for overseeing a 4,500 plus person group of departments in charge of financial reporting, credit and risk functions, operations and trade processing, facilities, security and corporate services. Prior to that, Mr. Zubrow was elected the firm's first chief credit officer, with responsibility for overseeing the entire firm's global credit exposures.
Throughout his career Mr. Zubrow has provided corporate finance and strategic advice for a wide range of investment banking clients including major Fortune 100 companies. He received his J.D. and M.B.A. from the University of Chicago and is an active board member for a number of non-profit organizations.
"We are pleased to welcome Barry to our board of directors," said Dr. Rathmann. "His vast financial and strategic experience will be a great asset to Nuvelo."
About Nuvelo
Nuvelo, Inc. is engaged in the discovery, development and commercialization of life improving therapeutics for the treatment of human disease. Nuvelo's lead product candidate, alfimeprase, is partnered with Amgen and is currently in two Phase 2 trials in two indications, peripheral arterial occlusion and catheter occlusion. Additional programs include cardiovascular product candidate ARC183 and drug discovery focused on antibody targets and secreted proteins.
Information about Nuvelo is available at our new Web site at www.nuvelo.com or by phoning 408-215-4000.
Source: Nuvelo, Inc. |
